Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Thorac Oncol. 2017 Oct 26;13(1):16–26. doi: 10.1016/j.jtho.2017.10.001

Fig. 3.

Fig. 3

Antigen targets in CAR T-cell therapy clinical trials for thoracic malignancies. The targets shown are compiled from clinical studies listed on ClinicalTrials.gov (last assessed on 7/20/17) that specifically target thoracic malignancies with CAR T cells. There are no targets currently employed for thymic cancer; however, MSLN is a potential therapeutic target for thymic carcinoma.33

CAR, chimeric antigen receptor; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; FAP, fibroblast activating protein; GPC3, glypican-3; HER2, human epidermal growth factor receptor 2; MSLN, mesothelin; MUC1, mucin 1; PD-L1, programmed death-ligand 1; PSCA, prostate stem cell antigen; ROR1, receptor tyrosine kinase-like orphan receptor 1